Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Hormone.

Thomas Jefferson University, Philadelphia, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Philadelphia, PA
Treatments:Chemotherapy, HormoneHospital:Thomas Jefferson University
Drugs:Journal:Link
Date:Mar 2012

Description:

Patients:
This phase III study involved men with previously untreated (other than surgery) metastatic castration-resistant prostate cancer who were divided into two separate treatment groups. Group A consisted of 524 patients with a median age of 68.8 years. Group B had 526 patients with a median age of 69.3 years.

Treatment:
Patients in Group A were treated with the chemotherapy agent docetaxel, the biologic therapy agent bevacizumab, and the hormone prednisone.
Patients in Group B were treated with docetaxel and prednisone only.

Toxicities:
There were 20 treatment-related deaths in Group A, the causes of which included heart attack, GI hemorrhage, and infection.
There were 6 deaths in Group B, the causes of which included heart attack and infection.

Results:
The median overall survival rates for groups A and B were 22.6 and 21.5 months, respectively.

Support:
This study was partially supported by the pharmaceutical company Roche-Genentech.

Correspondence: Dr. William Kevin Kelly; email: [email protected]



Back